Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma

Abstract Background Glioblastoma (GB) is incurable at present without established treatment options for recurrent disease. In this phase I first-in-human clinical trial we investigated safety and feasibility of adoptive transfer of clonal chimeric antigen receptor (CAR)-NK cells (NK-92/5.28.z) targe...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Neuro-oncology (Charlottesville, Va.) Jg. 25; H. 11; S. 2058 - 2071
Hauptverfasser:	Burger, Michael C, Forster, Marie-Therese, Romanski, Annette, Straßheimer, Florian, Macas, Jadranka, Zeiner, Pia S, Steidl, Eike, Herkt, Stefanie, Weber, Katharina J, Schupp, Jonathan, Lun, Jennifer H, Strecker, Maja I, Wlotzka, Karolin, Cakmak, Pinar, Opitz, Corinna, George, Rosemol, Mildenberger, Iris C, Nowakowska, Paulina, Zhang, Congcong, Röder, Jasmin, Müller, Elvira, Ihrig, Kristina, Langen, Karl-Josef, Rieger, Michael A, Herrmann, Eva, Bonig, Halvard, Harter, Patrick N, Reiss, Yvonne, Hattingen, Elke, Rödel, Franz, Plate, Karl H, Tonn, Torsten, Senft, Christian, Steinbach, Joachim P, Wels, Winfried S
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	US Oxford University Press 02.11.2023
Schlagworte:	Glioblastoma - pathology Humans Immunotherapy, Adoptive - methods Killer Cells, Natural Neoplasm Recurrence, Local - drug therapy Receptors, Chimeric Antigen Recurrence human clinical trial NK cells glioblastoma CAR in HER2 phase I first adoptive immunotherapy
ISSN:	1522-8517, 1523-5866, 1523-5866
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!